WEREWOLF THERAPEUTICS, INC. Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer of $21.00 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Income Statement › Other Income
us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2026-06-30 was $21.00M.
- WEREWOLF THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-12-31 was $0.00.
- WEREWOLF THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-09-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2023 was $19.94M, a 21.60% increase from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2022 was $16.40M.
- WEREWOLF THERAPEUTICS, INC. revenue from collaborative arrangement, excluding revenue from contract with customer for fiscal 2021 was $0.00.
| Period end | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 3 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 6 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 9 month | Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.00M S-4 · filed 2026-09-22 | $21.00M S-4 · filed 2026-09-22 | ||
| 2025-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 S-4 · filed 2026-09-22 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $0.00 S-4 · filed 2026-09-22 | $0.00 S-4 · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $1.14M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $1.14M derived: sum of 3 quarters · filed 2026-09-22 | $1.89M S-4 · filed 2026-09-22 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | $1.14M derived: sum of 2 quarters · filed 2025-11-04 | $1.89M 10-Q · filed 2025-11-04 | $3.39M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $1.14M 10-Q · filed 2025-08-14 | $1.89M 10-Q · filed 2025-08-14 | $3.39M derived: sum of 3 quarters · filed 2025-08-14 | $9.28M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $742.00K 10-Q · filed 2025-05-08 | $2.24M derived: sum of 2 quarters · filed 2025-05-08 | $8.14M derived: sum of 3 quarters · filed 2025-05-08 | $16.22M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $7.40M derived: sum of 2 quarters · filed 2025-03-11 | $15.48M derived: sum of 3 quarters · filed 2025-03-11 | $19.94M 10-K · filed 2025-03-11 |
| 2023-09-30 | $5.90M 10-Q · filed 2024-11-07 | $13.98M derived: sum of 2 quarters · filed 2024-11-07 | $18.44M 10-Q · filed 2024-11-07 | $25.73M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $8.08M 10-Q · filed 2024-08-08 | $12.54M 10-Q · filed 2024-08-08 | $19.83M derived: sum of 3 quarters · filed 2024-08-08 | $24.80M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.46M 10-Q · filed 2024-05-03 | $11.75M derived: sum of 2 quarters · filed 2024-05-03 | $16.72M derived: sum of 3 quarters · filed 2024-05-03 | $20.86M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $12.25M derived: sum of 2 quarters · filed 2024-03-07 | $16.40M derived: sum of 3 quarters · filed 2024-03-07 | $16.40M 10-K · filed 2024-03-07 |
| 2022-09-30 | $4.97M 10-Q · filed 2023-11-14 | $9.12M derived: sum of 2 quarters · filed 2023-11-14 | $9.12M 10-Q · filed 2023-11-14 | $9.12M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $4.15M 10-Q · filed 2023-08-10 | $4.15M 10-Q · filed 2023-08-10 | $4.15M derived: sum of 3 quarters · filed 2023-08-10 | $4.15M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | $0.00 derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |